ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pegloticase

Also written as “pegloticase”, “Pegloticase with MTX” and “Puricase”.

Its studies are mostly in Gout · Renal Insufficiency, Chronic, led by 3 companies.

Drug pagePegloticase: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 9, 201814 company-led studies, 1 open or runningNext primary completion: Jun 18, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen81 open or runningphase 4since Aug 9, 2018Aug 9, 2018Jun 18, 2028phase 3 · NCT07388498
Savient Pharmaceuticalsits history only50 open or runningphase 3since May 10, 2006Mar 24, 2004none ahead
Ampel BioSolutionsits history only10 open or runningphase 2since Oct 30, 2015Oct 30, 2015none ahead

Also a collaborator on its studies: IND 2 Results.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 9, 2018First study: phase 4 study in GoutFirst studyNCT03635957 · 14 enrolled · United States
  2. Jun 19, 2019Phase 4 study in GoutNCT03994731 · 152 enrolled · United States
  3. Sep 11, 2019Phase 4 study in Uncontrolled GoutNCT04087720 · 20 enrolled · United States
  4. Aug 11, 2020Phase 4 study in GoutNCT04511702 · 191 enrolled · United States
  5. Feb 12, 20212 phase 4 studies in GoutNCT04762498, NCT04772313
  6. Jan 19, 2024Phase 4 study in GoutNCT06229145 · 306 enrolled · United States
  7. Jan 29, 2026Phase 3 study in Uncontrolled GoutNCT07388498 · 270 planned · United States, Puerto Rico

Ahead

  1. Jun 18, 2028Primary completion: phase 3 study in Uncontrolled GoutNCT07388498

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07388498Uncontrolled Gout · United States, Puerto Rico3RecruitingJun 18, 2028270
NCT06229145Gout · United States4CompletedJul 30, 2025306
NCT04772313Gout · United States4CompletedAug 23, 202211
NCT04762498Gout · United States4CompletedMay 18, 202354
NCT04511702Gout · United States4CompletedJan 18, 2024191
NCT04087720Uncontrolled Gout · United States4CompletedJul 6, 202120
NCT03994731Gout · United States4CompletedMar 17, 2021152
NCT03635957Gout · United States4CompletedOct 23, 201914

How it is read

Names in the registry

  • “Pegloticase”, 9 entries
  • “pegloticase”, 2 entries
  • “Pegloticase with MTX”, 1 entry
  • “Puricase”, 1 entry
  • “pegloticase 8 mg i.v.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.